Dr Rangan Chatterjee#1 Aging Expert: Dementia, Diabetes & Heart Disease Start After 40 When You Ignore This
CHAPTERS
- 0:00 – 1:13
Why most people age poorly: reactive medicine vs proactive “health creation”
Dr. Chatterjee frames aging well as the most important long-term investment, then Dr. Comite argues modern healthcare is largely reactive—intervening only once symptoms or disease appear. They introduce the need for proactive monitoring and personal ownership of health to prevent (and even reverse) decline.
- •Healthcare systems mostly treat sickness rather than build health
- •Aging is inevitable, but decline is not—if you act early
- •Proactive testing and intervention can change long-term outcomes
- •“Own your health destiny” rather than waiting for diagnoses
- 1:13 – 5:29
“Pro-aging” in fantastic health: living longer without chronic disease
Comite distinguishes between chronological aging and biological aging, advocating a “pro-aging” mindset focused on vitality. They discuss rising life expectancy and why longer life is only valuable if you avoid dementia, heart disease, stroke, and frailty.
- •Chronological age increases, but biological youthfulness can be supported
- •Lifespan is increasing; healthspan must keep up
- •Chronic diseases can steal quality of added years
- •Being strong, capable, and mentally sharp late in life is achievable with planning
- 5:29 – 7:41
Aging accelerations: why decline becomes noticeable in the 30s–40s (and again in the 60s)
They explore research suggesting measurable shifts in aging biology occur in midlife. Comite explains why the 20s allow more “compensation,” while metabolic and hormonal changes in the 30s and 40s set the stage for later disease—often without obvious symptoms.
- •You can ‘get away with’ more in your 20s; less so in your 30s
- •Hormones and metabolism shift before symptoms appear
- •Men can show heart disease risk as early as late 30s
- •Published data suggests aging shifts are prominent in the 40s and again in the 60s
- 7:41 – 8:49
Chronic disease doesn’t start suddenly: decades-long runway to diabetes, heart attacks, and dementia
Comite emphasizes that heart disease, diabetes complications, and cognitive decline develop over decades, not weeks. The key failure in today’s system is late detection—often 10–30 years after the earliest metabolic warning signs.
- •Heart attacks and type 2 diabetes are usually decades in the making
- •Insulin resistance often precedes diabetes by many years
- •Symptoms and ‘normal’ tests can hide brewing pathology
- •Early course correction is easier than late-stage disease management
- 8:49 – 14:54
Why ‘normal ranges’ can mislead: population averages vs individual trends
They critique standard checkups (e.g., at 40) that rely on broad population-based reference ranges and one-off measurements. Comite argues that ‘normal’ is often derived from an unhealthy population and that what matters is the individual’s direction of travel over time.
- •One-time screening is limited; trends are more meaningful
- •Reference ranges reflect population averages, not personal optimal
- •“Normal” can still mean deteriorating metabolic health
- •Vague midlife symptoms often get dismissed without deeper investigation
- 14:54 – 16:42
The 5 biomarkers of “True Health”: simplifying what to track
Comite introduces her core framework—five biomarkers intended to capture key aging-related risk domains while avoiding data overwhelm. She explains how her clinical-scientist background and real-world longitudinal patient data shaped this short list.
- •Framework designed to be practical and actionable
- •Biomarkers focus on early detection of aging-related dysfunction
- •Includes deep carbohydrate metabolism markers plus lipid risk ratio
- •Adds a hormone marker most clinicians overlook: free testosterone
- 16:42 – 25:00
Carbohydrate metabolism triad: fasting glucose, HbA1c, and fasting insulin
They dive into why these three markers must be interpreted together and why fasting insulin is a crucial early-warning signal. Comite argues that insulin resistance is widespread and drives many diseases of aging beyond diabetes alone.
- •Fasting insulin changes decades before diabetes diagnosis
- •HbA1c can look ‘fine’ while glucose swings are harmful
- •Insulin resistance links to cancer and bone health, not just diabetes
- •Most people show some degree of carbohydrate-metabolism dysregulation with age
- 25:00 – 25:58
How often to test—and why feedback loops matter
Comite and Chatterjee agree that annual testing is often too infrequent for behavior change. They discuss testing 2–4 times per year depending on risk and emphasize that timely feedback increases adherence and makes interventions measurable.
- •Ideal frequency depends on risk profile and health history
- •Quarterly testing can help connect lifestyle changes to outcomes
- •Seeing improvement reinforces behavior change
- •The goal is not just numbers, but trajectory and course correction
- 25:58 – 45:06
Continuous glucose monitors (CGMs): turning invisible physiology into daily insight
They discuss CGMs as a tool for personalized learning—showing how food order, alcohol, sleep, and illness affect glucose. Both share personal examples (sweet potatoes, illness effects) and how CGMs can guide experiments rather than rigid rules.
- •CGMs reveal individualized responses (banana vs cookie example)
- •Food sequencing (protein first) can flatten glucose spikes
- •Alcohol can trigger night-time glucose drops and insomnia
- •A 14-day CGM ‘audit’ can teach lifelong lessons; repeat after a change for comparison
- 45:06 – 55:04
Testosterone as an aging biomarker: metabolism, muscle, brain, and bone (not just libido)
Comite reframes testosterone as a critical hormone for both men and women, influencing muscle, visceral fat, insulin sensitivity, cognition, and bone density. She shares clinical cases and her own long-term testosterone use to prevent osteoporosis progression.
- •Testosterone declines ~1–3% per year after ~30
- •Optimization can improve body composition, glucose control, and cognition
- •Comite’s twin comparison illustrates long-term bone-protection potential
- •Low testosterone is associated with multiple ‘diseases of aging’
- 55:04 – 1:06:25
Lifestyle vs hormones: can you raise testosterone naturally—and what is hCG?
They clarify that lifestyle prevents unnecessary drops but often can’t restore testosterone to an ‘optimal’ range in midlife. Comite explains hCG as a peptide that stimulates a man’s own testosterone production, dosing patterns, and when direct testosterone may be needed.
- •Good sleep/stress control prevents suppression but may not reach ‘optimal’
- •Exercise boosts growth hormone synergy but doesn’t reliably raise testosterone
- •hCG mimics LH to stimulate testicular production; typically twice weekly
- •Responsiveness varies; protocols may adjust to 3x/week or add testosterone
- 1:06:25 – 1:09:21
Safety considerations: monitoring, dosing, and the polycythemia risk
Comite addresses concerns about “playing with nature” and outlines key risks primarily related to excessive dosing or poor monitoring. She highlights erythrocytosis/polycythemia as a manageable but important side effect requiring lab surveillance and sometimes phlebotomy or blood donation.
- •Physiologic dosing differs from anabolic steroid misuse
- •Main risk discussed: elevated hematocrit/hemoglobin (polycythemia)
- •Risk can vary by individual factors (e.g., high-altitude upbringing)
- •Requires monitoring and corrective steps (dose changes, phlebotomy, donation)
- 1:09:21 – 1:17:52
Women and testosterone: weight, bone, libido, and menopause complexity
Comite argues women need testosterone too (made in ovaries and adrenals) and links low levels to truncal weight gain, bone loss risk, and reduced vitality. She discusses perimenopause/menopause hormone needs (estrogen, progesterone, testosterone), and clinical nuances like protecting the endometrium with progesterone.
- •Testosterone supports women’s muscle, bone, cognition, and sexual health
- •Birth control can lower testosterone and contribute to weight gain/bone effects
- •Menopause is a ‘cliff’ vs men’s gradual decline; women vary widely
- •Perimenopause requires attention to unopposed estrogen and endometrial risk
- 1:17:52 – 1:33:33
Defying genetic destiny at scale: N-of-1 medicine, apps, and “Who do you want to be at 100?”
They connect family history to gene expression and emphasize epigenetics—how choices can alter outcomes even with high genetic risk. Comite outlines her vision for app-based, AI-assisted, credentialed “health creation” using longitudinal personal data, ending with a reflective question to motivate long-term planning.
- •Family history is gene expression; epigenetics shapes how genes manifest
- •Personalized interpretation is the missing link—not just more testing
- •Virtual care and apps can scale proactive prevention like banking apps did
- •The ‘100-year-old self’ question reframes priorities toward healthspan
